Deverra Therapeutics

Did you know that July is #cordblood awareness month? At Deverra, umbilical cord blood is central to who we are and the cell therapies we are developing. It's even in our name! Read the story behind our name below. #cordbloodawareness #cordblooddonation #savetheCordBloodsavetheworld #celltherapy #allogeneic

Thanks to the organizers of the Allogeneic Cell Therapy Summit for inviting Colleen Delaney to participate. Dr. Delaney was on a panel discussing the ideal starting material for allogeneic cell therapies and presented a plenary talk on Deverra's pooled cord blood donor manufacturing that results in a scalable, consistent and cost-effective approach for the generation of cellular immunotherapies. Our lead asset, #dilanubicel, was just granted #RMAT, #FastTrack and #OrphanDrug designations for treatment of AML using this manufacturing approach. The future of #allogeneic cell therapies is bright!! 😎 Next up: come see presentations by Deverra Therapeutics at the annual #CordBloodConnect and #CARTCR summit in September! Stay tuned for more details! #cordblood #AML #celltherapy

How are new drugs developed??? It can be a very long process, but Deverra is well on its way with its lead cell therapy asset, dilanubicel. #celltherapy #allogeneic #AML

How are new drugs developed??? It can be a very long process, but Deverra is well on its way with its lead cell therapy asset, dilanubicel. #celltherapy #allogeneic #AML

We are excited to announce that Deverra will have multiple presentations at the upcoming ISCT, International Society for Cell & Gene Therapy meeting taking place May 29-June 1, 2024, in Vancouver, BC, Canada. These presentations will focus on Deverra's use of pooled donor manufacturing of dilanubicel to overcome the barriers associated with allogeneic cell therapy development (Abstract #810), Deverra's breakthroughs in generating therapeutically relevant quantities of highly functional allogeneic monocytes and macrophages from pooled donor umbilical cord blood stem cells (Abstract #989), and Deverra’s partnership with Coeptis Therapeutics in the development of an antigen agnostic universal donor SNAP-CAR natural killer cell therapy by integrating Coeptis’ SNAP-CAR technology with Deverra’s universal NK cell generation platform (Abstract #6). At Deverra, we remain committed to advancing the frontiers of next-generation cellular immunotherapies with the goal of making life-saving cell therapies accessible and affordable for everyone. We look forward to attending the conference to hear about all the great work happening in the cell and gene therapy field and to meet new people, make new connections and forge new collaborations. Come see us!! Details on the dates/times of the four presentations at the ISCT meeting are as follows: Poster Presentations: Wednesday, May 29, 2024 (7-8:30 PM) 🙌 Developing a First-In-Class Universal Allogeneic SNAP-CAR NK Cell Therapy 🙌 Overcoming Current Challenges in Allogeneic Cell Therapy Manufacturing by Using Pooled Donor Cord Blood CD34+ Cells as Starting Material 🙌 Generation of Monocytes and Macrophages from CD34+ Cord Blood Cells for Cell Therapy Oral Presentation: Thursday, May 30, 2024 (8:00 -9:00 AM) 🎉 Developing a First-In-Class Universal Allogeneic SNAP-CAR NK Cell Therapy #ISCT #Allogeneic #CellTherapy #Universal

That's a wrap for ASGCT! Thanks to all who stopped by our poster presentations to learn more about Deverra and a big shout out to our Director of Cell Biology, Carrie Stoltzman, for representing our platform and the amazing work we are doing at Deverra Therapeutics in generating universal donor allogeneic cellular immunotherapies with a goal of making remission a reality for all. Did you miss us? We will be at ISCT, International Society for Cell & Gene Therapy as well. Stay tuned for more information about our presentations soon! #ASGCT #CordBloodCellTherapies #Allogeneic #UniversalDonor #SeekingRemissionforAll

If you’re at #ASGCT in Baltimore this week, stop by our posters and say hi!

🤩 👏 We are excited to announce that Deverra will have multiple presentations highlighting the progress made on our universal allogeneic cellular immunotherapy pipeline at the upcoming annual meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 7-11, 2024, in Baltimore, MD. Carrie Stoltzman, Director of Cell Biology, will be presenting data from Deverra’s research programs during three poster sessions at the ASGCT meeting. These presentations will focus on Deverra's utilization of pooled donor manufacturing to overcome the barriers associated with allogeneic cell therapy development (Abstract #859),  Deverra's breakthroughs in generating therapeutically relevant quantities of highly functional allogeneic monocytes and macrophages from pooled donor umbilical cord blood stem cells (Abstract #1797), and Deverra’s partnership with Coeptis Therapeutics in the development of a universal SNAP-CAR natural killer cell therapy from pooled donor umbilical cord stem cells (Abstract #1325), showcasing its commitment to advancing the frontiers of next-generation of cellular immunotherapies. Details on the dates/times of the three presentations at the ASGCT meeting are as follows: 1) “Overcoming Current Challenges in Allogeneic Cell Therapy Manufacturing by Using Pooled Donor Cord Blood CD34+ Cells as Starting Material” ·        Abstract Number: 859 ·        Session Date/Time: Wednesday, May 8, 2024 5:30 PM – 7:00 PM ·        Session Title: Cell Therapy Product Engineering, Development, and Manufacturing 2) “Developing a First-In-Class Universal Allogeneic SNAP-CAR NK Cell Therapy” ·        Abstract Number: 1325 ·        Session Date/Time: Thursday, May 9, 2024 5:30 PM – 7:00 PM ·        Session Title: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies 3) “Generation of Monocytes and Macrophages from CD34+ Cord Blood Cells for Cell Therapy” ·        Abstract Number: 1797 ·        Session Date/Time: Friday, May 10, 2024 5:30 PM – 7:00 PM ·        Session Title: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies Deverra Therapeutics invites ASGCT conference attendees to visit its poster presentations to learn more about its research and to engage with its team of experts.

Our crowd investing campaign has been live for just over 4 weeks now and we are so honored and excited to welcome so many new investors into our family. We want to extend our sincerest gratitude to you, all 257 of you, for your invaluable investment dedicated to advancing the development of our revolutionary universal cell therapy drug for improving remission rates in patients with newly diagnosed leukemia. Being diagnosed with cancer comes with so many uncertainties, including whether or not remission will be achieved after therapy or at all. At Deverra, our goal is to take that uncertainty out of the equation. To our new investors and champions: please continue to spread the word about this opportunity to your networks, family and friends and invite them to join you in investing. Not yet an investor? There’s still time to join us! We invite you to check out our campaign page (https://lnkd.in/g4nH69Ka) and website (www.deverratx.com), and become a part owner of Deverra by visiting (https://lnkd.in/gKg5CdfX).      #leukemia #AML #SeekingRemissionforAll #celltherapy #beatAML #dilanubicel

Deverra is thrilled to announce that dilanubicel was granted Fast Track designation for the treatment of AML to improve response with upfront therapy. This is the third regulatory designation for dilanubicel in as many months. We are excited to move this product forward and bring hope to patients diagnosed with AML. #FastTrack #leukemia #AML #SeekingRemissionforAll #dilanubicel